Takeda Pharmaceutical Company Limited
TAK
$18.37
$0.090.49%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.21% | -86.54% | -1.63% | -30.09% | 7.52% |
| Total Depreciation and Amortization | -1.32% | -2.40% | -0.94% | -1.79% | -0.33% |
| Total Amortization of Deferred Charges | 20.80% | 20.80% | 20.80% | 20.80% | 13.61% |
| Total Other Non-Cash Items | 146.97% | 286.41% | 1,371.93% | 133.10% | 596.81% |
| Change in Net Operating Assets | -3,506.34% | 130.09% | 85.67% | 78.78% | 99.23% |
| Cash from Operations | 7.59% | 37.23% | 37.79% | 41.43% | 40.16% |
| Capital Expenditure | 7.95% | 7.64% | -2.47% | -8.34% | -9.35% |
| Sale of Property, Plant, and Equipment | 13,863.39% | 2,042.95% | -24.95% | -99.13% | -99.52% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 52.36% | 52.53% | 111.70% | 0.51% | 211.03% |
| Other Investing Activities | 16.23% | 57.54% | 46.11% | 46.27% | 69.17% |
| Cash from Investing | 18.87% | 40.73% | 30.94% | 27.02% | 56.63% |
| Total Debt Issued | -45.81% | -48.45% | 7.89% | 179.03% | 106.36% |
| Total Debt Repaid | 36.30% | -68.18% | -329.24% | -263.86% | -154.68% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -5,297.50% | -5,297.50% | -5,297.50% | -2,129.58% | 19.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -6.79% | -7.05% | -7.12% | 2.38% | 3.33% |
| Other Financing Activities | -64.40% | -87.93% | -718.44% | -24.60% | -39.09% |
| Cash from Financing | -40.95% | -3,442.56% | -534,540.79% | -103.83% | -61.57% |
| Foreign Exchange rate Adjustments | 208.29% | 232.77% | -212.44% | -145.49% | -55.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.62% | -131.24% | -193.97% | 17.97% | 145.91% |